Verastem's CEO Dan Paterson discusses the launch of the Avmapki Fakzynja Co-Pack for KRAS-mutated recurrent low-grade serous ovarian cancer, and other pipeline projects

blonca9
Sep 8
1 min read

He discusses the launch of this combination, which was an accelerated approval, and arrived a couple of months sooner than the scheduled FDA decision date. Plus, why the confirmatory study is important, and pipeline progress on the G12D space.

Coverage brought to you by:

Recent Posts

See All

Jack Silberstein's startup, Deck Bio, received a "Golden Ticket" award from Servier - he and Servier's Irene Blat discuss how it is one of the many ways larger companies help biotech entrepreneurs

This year, our industry has seen many programs held up by CMC issues. As Genezen Chairman & CEO Steve Favaloro describes, having a quality and compliance mindset is key

Mizuho Senior Analyst Graig Suvannavejh shares his take on biotech and companies he covers that are in the news with key catalysts

Verastem's CEO Dan Paterson discusses the launch of the Avmapki Fakzynja Co-Pack for KRAS-mutated recurrent low-grade serous ovarian cancer, and other pipeline projects

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight